Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Asian Pac J Cancer Prev. 2021 Jan 1;22(1):3-10. doi: 10.31557/APJCP.2021.22.1.3.
Genetic polymorphisms can influence the chemotherapeutic response; however, previous studies have produced conflicting results, and have failed to identify the most relevant polymorphisms for predicting the response to treatment in patients with cancer. The present meta-analysis was conducted to determine the correlation between two polymorphisms (rs1045642 and rs1128503) in ATP-binding cassette transporter B subfamily member 1 (ABCB1), which is associated with multidrug resistance, and the survival of patients treated with taxane-containing chemotherapy.
Several databases, including PubMed and Embase, were used to retrieve articles evaluating the association between the ABCB1 rs1045642 and rs1128503 polymorphisms and survival, published prior to August 2019. The meta-analysis was conducted using R software to determine the pooled hazard ratio (HR) and 95% confidence intervals (95% CIs).
Fifteen studies involving 3320 patients were included in the meta-analysis. The effect of the rs1128503 polymorphism on progression-free survival remained significant in the heterozygote (HR 0.81; 95% CI: 0.67-0.98) and homozygote (HR 0.71; 95% CI: 0.58-0.88) models. The TT genotype rs1128503 was associated with better overall survival (HR 0.72; 95% CI: 0.53-0.97).
Carriers of the rs1128503 T allele of ABCB1 showed a survival benefit after taxane-containing chemotherapy.
遗传多态性可能会影响化疗反应；然而，先前的研究结果相互矛盾，且未能确定与癌症患者对治疗的反应预测最相关的多态性。本荟萃分析旨在确定与多药耐药相关的 ABCB1 基因中的两个多态性（rs1045642 和 rs1128503）与接受紫杉烷类化疗的患者的生存之间的相关性。
检索了包括 PubMed 和 Embase 在内的多个数据库，以获取评估 ABCB1 rs1045642 和 rs1128503 多态性与生存之间相关性的文章，这些文章发表于 2019 年 8 月之前。使用 R 软件进行荟萃分析，以确定合并风险比（HR）和 95%置信区间（95%CI）。
荟萃分析纳入了 15 项涉及 3320 名患者的研究。rs1128503 多态性对无进展生存期的影响在杂合子（HR 0.81；95%CI：0.67-0.98）和纯合子（HR 0.71；95%CI：0.58-0.88）模型中仍然显著。rs1128503 的 TT 基因型与更好的总生存期相关（HR 0.72；95%CI：0.53-0.97）。
ABCB1 基因 rs1128503 的 T 等位基因携带者在接受紫杉烷类化疗后具有生存获益。
